UBX1325
UBX1325 has been studied in 6 papers since 2022: 3 trials in people, 3 reviews; 2 in the past year. The newest paper, May 6, 2026: “Single-cell insights into maladaptive endothelial plasticity and therapeutic targets in diabetic vascular complications”.
At a glance
The findings reach people, from one lab or study. 2 independent labs in 2 countries; 3 trials, 2 about aging.
“the difference between UBX1325 and sham in mean change to week 48 in best corrected visual acuity was 5.6 more ETDRS letters (95% confidence interval, -1.5 to 12.7)”
None of its findings points the other way.
- 2 independent labs in 2 countries
- 3 trials, 2 about aging
- 7 of 7 findings with company ties
- 3 of 3 trials sponsored by its developers
- Human trial3
Studies in people
2 studies gave UBX1325 to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
up: Increases best-corrected visual acuity5.6 more ETDRS letters vs sham (95% CI -1.5 to 12.7) no change: Has no effect on treatment discontinuation due to treatment-emergent adverse events no change: Has no effect on vital signs, electrocardiograms and routine blood chemistries | Randomized trialweek 48 | 65 peopleBothDiabetic macular edema with prior suboptimal response to anti-VEGF treatment | NEJM evidence, Apr 22, 2025 |
up: Improves best-corrected visual acuity+6.2 ETDRS letters at Week 8, p = 0.02 up: Improves mfERG N1-P1 response density+14% at Week 8 | Treated cohort48 weeks | 5 peopleNAMD subjects with active disease despite treatment | Journal of clinical medicine, Sep 19, 2024 |
What did studies of UBX1325 find?
7Studies of UBX1325 measured 7 outcomes, among them best-corrected visual acuity, endothelial-to-mesenchymal transition and Vital signs, electrocardiograms and routine blood chemistries.
Best-corrected visual acuity
upin humans1
1 study
Best-corrected visual acuity
upin humans1
UBX1325 increases best-corrected visual acuity in neovascular AMD subjects with prior anti-VEGF injections (+5 letters at Week 4 (p = 0.02); +6.2 letters at Week 8 (p = 0.02)).
“The mean change in BCVA demonstrated statistical significance in Weeks 4 and 8, showing increases of 5 (p = 0.02) and 6.2 (p = 0.02) letters, respectively.”
Human trialin neovascular AMD subjects with prior anti-VEGF injections50 μL intravitreal injectionn = 5
Journal of clinical medicine
UBX1325 improves best-corrected visual acuity in humans (+6.2 ETDRS letters at Week 8, p = 0.02).
“Mean change in BCVA demonstrated statistical significance at Weeks 4 and 8, showing increases of 5 (p = 0.02) and 6.2 (p = 0.02) ETDRS letters, respectively.”
Human trial48 weeksn = 5
Journal of clinical medicine
endothelial-to-mesenchymal transition
downin reviews1
1 study
endothelial-to-mesenchymal transition
downin reviews1
UBX1325 prevents endothelial-to-mesenchymal transition (proposed in combination with TGF-β or SETD7 inhibition).
“coupling senolytics, such as UBX1325, with anti-fibrotic strategies like TGF-β or SETD7 inhibition to prevent irreversible EndoMT”
Reviewproposed in combination with TGF-β or SETD7 inhibition
Cardiovascular diabetology
Vital signs, electrocardiograms and routine blood chemistries
no changein humans1
1 study
Vital signs, electrocardiograms and routine blood chemistries
no changein humans1
UBX1325 showed no clear effect on vital signs, electrocardiograms and routine blood chemistries in humans.
“There were no apparent between-group differences with respect to vital signs, electrocardiograms, or routine blood chemistries.”
Human trial10 μg single intravitreal injectionup to 48 weeksn = 65
Safety and Efficacy of Senolytic UBX1325 in Diabetic Macular Edema
NEJM evidence
Treatment discontinuation due to treatment-emergent adverse events
no changein humans1
1 study
Treatment discontinuation due to treatment-emergent adverse events
no changein humans1
UBX1325 showed no clear effect on treatment discontinuation due to treatment-emergent adverse events in humans.
“In this sham-controlled trial there were no TEAEs that led to discontinuation of treatment with UBX1325 compared with sham.”
Human trial10 μg single intravitreal injectionup to 48 weeksn = 65
Safety and Efficacy of Senolytic UBX1325 in Diabetic Macular Edema
NEJM evidence
Best-corrected visual acuity
upin humans1
1 study
Best-corrected visual acuity
upin humans1
UBX1325 increases best-corrected visual acuity in humans (diabetic macular edema with prior suboptimal response to anti-VEGF treatment) (5.6 more ETDRS letters vs sham (95% CI -1.5 to 12.7)).
“the difference between UBX1325 and sham in mean change to week 48 in best corrected visual acuity was 5.6 more ETDRS letters (95% confidence interval, -1.5 to 12.7)”
Human trialdiabetic macular edema with prior suboptimal response to anti-VEGF treatment10 μg single intravitreal injectionweek 48n = 65
Safety and Efficacy of Senolytic UBX1325 in Diabetic Macular Edema
NEJM evidence
Multifocal electroretinography N1-P1 response density
upin humans1
1 study
Multifocal electroretinography N1-P1 response density
upin humans1
UBX1325 increases multifocal electroretinography N1-P1 response density in neovascular AMD subjects with prior anti-VEGF injections (≥20% gain in three of five subjects at Week 8).
“After foselutoclax treatment, the largest improvement in the mfERG N1-P1 response density occurred at Week 8 as three of five subjects achieved a ≥20% gain.”
Human trialin neovascular AMD subjects with prior anti-VEGF injectionsretina50 μL intravitreal injectionn = 5
Journal of clinical medicine
More on Multifocal electroretinography N1-P1 response density
mfERG N1-P1 response density
upin humans1
1 study
mfERG N1-P1 response density
upin humans1
UBX1325 improves mfERG N1-P1 response density in humans (+14% at Week 8).
“The total N1-P1 response density did not reach statistical significance at any visit but did have a noteworthy gain of 14% at Week 8 compared to baseline.”
Human trial48 weeksn = 5
Journal of clinical medicine
Has UBX1325 been tested in people?
2 of 3 about agingYes: 3 trials in people have been published.
Who is developing UBX1325?
1 company: Unity Biotechnology.
- Companies
- Unity BiotechnologyPhase 2neovascular age-related macular degeneration, diabetic macular edema
Trial sponsors
Company3 trialsPhase 2135 people